

Synthesis Of Dibenzofuran-1,3-Thiazole Carboxamide Derivatives And Screened For Anti-Inflammatory Potential

Shubham Singh^{1*}, Dr. Arun Patel², Dr. Shailendra Patel³

^{1*,2,3}SRGI- Shri Ram Group of Institution, Department of pharmacy, Jabalpur-482002, Madhya Pradesh, India

***Corresponding Author:** Shubham Singh

*Email ID: Shubhamsingh21446@gmail.com, Mobile No.: 9340164713

ABSTRACT

Objective: Synthesis of dibenzofuran-1,3-thiazole carboxamide derivatives and screened for anti-inflammatory potential

Material and methods: The goal of the current study was to synthesize a few dibenzofuran-1,3-thiazolecarboxamide derivatives using four-step processes and several substituted benzylamines with the help of an appropriate catalyst. The following compounds were prepared: compound 1 (S-((4-chlorodibenzo[b,d]furan-1-yl)methyl) thiohydroxylamine), compound 2 (ethyl 2-(4 chlorodibenzo[b,d]furan-1-yl)-5-methylthiazole-4-carboxylate), compound 3 (2-(4-chlorodibenzo[b,d]furan-1-yl)-5 methylthiazole-4-carboxylic acid), and compound 4 (N-benzyl-2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methyl thiazole 4-carboxamide). Compounds TC-1 through TC-14 are the codes for Compound 4. A total of twelve compounds have been created in these four processes, and the protein denaturation assay has been used to assess each compound's potential for reducing inflammation.


Result and Discussion: The IR spectrum of the compounds has shown the characteristics peak (cm⁻¹) of N-H at 3412; C=C-H at 3470; C=O at 1735; C=C at 1624–1446; C-N at 1015; p-substitution at 792; C-F at 1102; C-Cl at 855; C-Br at 1015; N-O at 1356; N=O at 1558. The ¹HNMR spectra of Final compounds (TC-1 to TC-12) depicted the peak at 2.90 (3H, CH₃); 4.64 - 4.65 (2H, CH₂); 7.05-7.10 (2H, Ar-H); 7.35 (1H, Ar-H); 7.33 – 7.39 (4H, Ar-H); 7.45 (1H, Ar-H); 7.48 - 7.50 (1H, Ar-H); 7.62 - 7.63 (1H, Ar-H); 7.90 - 7.92 (1H, Ar-H); 8.38 – 8.40 (1H, N-H). Compound TC-1, mass spectrum has shown peak at m/z = 450.85, which matches the chemical formula C₂₄H₁₆ClFN₂O₂S. The protein denaturation assay of synthesized compound stated that most active compound are TC-1, TC-2, TC-3, TC-4 and TC-5 and compounds TC-7 & TC-9 has shown the mild activity and compound TC-6, TC-8, TC-10, TC-11 and TC-12 has shown modest activity.

Conclusion: The substitution of fluoro, chloro, bromo, iodo, and nitro was one of the main groups that significantly increased the activity with para-substituent.


Keywords: Thiazole, Anti-inflammatory, Protein Denaturation Assay

INTRODUCTION:


One of the most intricate areas of chemistry is the study of heterocyclic compounds. Heterocyclic compounds are abundant in nature and are crucial for controlling various biological processes. Chemotherapeutic agents, medications, dyestuffs, and copolymers are among the many uses for heterocyclic compounds. Benzofuranes are a particularly intriguing class of heterocyclic compounds that contain oxygen and have a wide range of applications in synthetic and medicinal chemistry. Benzofuranes, which are found in coal tar and are isolated as picrate, have a significant role in medicine and insecticides. Another synthetic technique is the Palladium-protonated cyclization of O-substituted aryl aryl ether. Numerous artificial derivatives of benzofurans possess intriguing characteristics. These are also employed as step-ins in the manufacturing of fungicides, herbicides, and parasiticides.



Condensation of a benzene ring at the 2,3, or 3,4 position results in the formation of benzofuran, depending on the benzene ring's location. One is called iso-coumaran or iso-benzofuran, while the other is called coumaran (or) benzofuran.



benzo (b) furan



benzo (c) furan

The benzofuran nucleus is found in coal tar and is extracted as picrate. It has significant value in medicines and pesticides. It is also synthesized by cyclizing O-substituted aryl aryl ether by palladium protonation. Numerous artificial benzofuran compounds possess intriguing characteristics. These are further employed as intermediaries in the manufacturing of fungicides, herbicides, and parasiticides. Numerous biological actions have been linked to benzofurans; in particular, dibenzofurans have been shown to have analgesic, antiviral, anti-inflammatory, cough-inhibiting, hypo-lipidemic, and herbicidal effects.

The creation of novel molecules that are effective and pharmaceutically active is the biggest benefit of heterocyclic chemistry. Chemical reactions occur at every stage of the synthesis process; also, the conditions and reagents must be chosen to produce pure molecules and high yields. Because of their unique properties, heterocyclic compounds may find use in the management of infectious disorders. An important advance in the history of contemporary medicine has been the discovery and development of an efficient anti-inflammatory drug. A review of the literature revealed that the creation of pharmacologically relevant compounds involved the use of thiazole and its derivatives. It was intended to create a few novel bioactive compounds with thiazole moiety in light of these findings.

INFLAMMATION

Your body's white blood cells and the substances they produce, known as inflammation, serve as a defense against infections brought on by external invaders like bacteria and viruses. However, in certain illnesses, such as arthritis, your immune system—your body's defensive mechanism—induces inflammation even in the absence of outside invaders to repel. Your immune system damages ordinary tissues in certain autoimmune illnesses by acting as though they are abnormal or contaminated.

Inflammation Types:- Inflammation can be either short-lived (acute) or long-lasting (chronic). Acute inflammation goes away within hours or days.


MATERIALS AND METHOD:

Methanesulfonic acid, potassium thiocyanate, 4 chlorobenzo [b,d] furan, potassium carbonate, ethyl-3 bromo-2-oxocutanoate, potassium ethanol, dichloromethane, hydroxide, triethylamine and substituted benzyl amine were purchased from sigma Aldrich. All solvents used for the reactions were distilled before use.

Synthesis Scheme:-he synthesis of the final compound was achieved through four Schemes.


- **Scheme-I:** Synthesis of S-((4-chlorodibenzo[b,d]furan-1-yl)methyl) thiohydroxylamine
- **Scheme-II:** Synthesis of ethyl 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methylthiazole-4 carboxylate
- **Scheme-III:** Synthesis of 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methylthiazole-4-carboxylic acid
- **Scheme-IV:** Synthesis of N-benzyl-2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methyl thiazole-4 carboxamide

Scheme-I: Synthesis of S-((4-chlorodibenzo[b,d]furan-1-yl)methyl) thiohydroxyl amine




Procedure: 4-chlorodibenzo[b,d]furan (0.02M) Compound 1, was taken in round bottomed flask and dissolved in 20 ml of methane sulfonic acid. The mixture then stirred for 10 min. Then potassium thiocyanate (0.02M) was added slowly to above mixture and reaction was kept at 0–5°C in salt-ice and the reaction mixture was stirred at room temperature for 15min. The reaction mixture was poured into crushed ice, to obtained the solid product (Compound 2), was filtered and then triturated with n-hexane to get a pale brown colour solid. Yield-82%; Mass m/z: 263.74

Scheme-II: Synthesis of ethyl 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methylthiazole-4-carboxylate




Procedure: S-((4-chlorodibenzo[b,d]furan-1-yl)methyl) thio hydroxylamine (0.02M) Compound 2, was dissolved in 15ml ethanol and stirred for 15 min. Then potassium carbonate (0.02M) followed by ethyl 3-bromo-2-oxobutanoate (0.02M) was added at room temperature. The reaction mixture was refluxed at 80°C for 2 hrs. with occasional shaking, subsequently it was poured into 50 ml of cold water and the precipitate which obtained was filtered to get a peach colored solid[43] (Compound 3), yield –72.50%; Mass (m/z): 371.84.

Scheme-III: Synthesis of 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methylthiazole-4-carboxylic acid



Procedure: The ethyl 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methylthiazole-4-carboxylate(0.01M), (Compound 3) was dissolved in 15 ml of ethanol and potassium hydroxide (0.02M) was added followed by addition of 20 ml distilled water and stirred at room temperature for 2hrs. Subsequently the reaction mixture was poured into cold water, acidified with 1NHCl (pH3) and precipitated solid was filtered and triturated with ether followed by n-hexane to give off-white solid[44] (Compound 4); Yield:- 72% Mass (m/z): 343.78.

Scheme-IV: Synthesis of N-benzyl-2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methylthiazole-4-carboxamide



Procedure: In a 50ml round bottom flask 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methylthiazole-4 carboxylic acid (0.02M), (Compound 4) was dissolved in 10 ml dichloromethane. 0.32g (0.002M) of TBTU and 0.15 ml (0.002M) of triethylamine were added to that solution, and it was agitated for five minutes in a nitrogen environment. Next, for three hours, substituting benzyl amine (0.02M) was added and mixed. below the ambient temperature. Ethyl acetate was used to extract the reaction mixture as the reaction was being monitored for completion using TLC. To obtain a solid product, the organic layer was removed and dried on anhydrous sodium sulphate after being cleaned with sodium bicarbonate solution, water, and brine solution. (Compound 5)

Table No. 1:- Quantity of chemicals taken

| S. NO. | Name of Chemicals | Mol. Formula | Mol. Weight | Quant. (gm) |
|--------|---|---|-------------|-------------|
| 1 | 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methylthiazole-4 carboxylic acid | C ₁₇ H ₁₀ ClNO ₃ S | 343.78 | 6.87 |
| 2 | N-chloro-1-(4-fluorophenyl)methanamine | C ₇ H ₇ ClFN | 159.59 | 3.19 |
| 3 | N-chloro-1-(4-Chlorophenyl)methanamine | C ₇ H ₇ Cl ₂ N | 176.04 | 3.52 |
| 4 | N-chloro-1-(4-bromophenyl)methanamine | C ₇ H ₇ BrClN | 220.49 | 4.40 |
| 5 | N-chloro-1-(4-Iodophenyl)methanamine | C ₇ H ₇ ClIN | 267.49 | 5.34 |
| 6 | N-chloro-1-(4-nitrophenyl)methanamine | C ₇ H ₇ ClN ₂ O ₂ | 186.60 | 3.72 |
| 7 | N-chloro-1-(4-methylphenyl)methanamine | C ₈ H ₁₀ ClN | 155.63 | 3.11 |
| 8 | N-chloro-1-(4-methoxyphenyl)methanamine | C ₈ H ₁₀ ClNO | 171.62 | 3.43 |
| 9 | N-chloro-1-(4-ethylphenyl)methanamine | C ₉ H ₁₂ ClN | 169.65 | 3.39 |
| 10 | N-chloro-1-(4-ethoxyphenyl)methanamine | C ₉ H ₁₂ ClNO | 185.65 | 3.71 |
| 11 | N-chloro-1-(4-(trifluoromethyl)phenyl)methanamine | C ₈ H ₇ ClF ₃ N | 209.60 | 4.19 |
| 12 | N-chloro-1-(4-propylphenyl)methanamine | C ₁₀ H ₁₄ ClN | 183.68 | 3.67 |
| 13 | N-chloro-1-(4-propyloxyphenyl)methanamine | C ₁₀ H ₁₄ ClNO | 199.68 | 3.99 |

CHARACTERIZATION OF THE SYNTHESIZED COMPOUNDS

Table No. 2: Physicochemical properties and list of final synthesized compounds

| S. No. | Code | Chemical Name | Mol. Weight | Chemical Formula | Perc ent Yield | Melting point |
|--------|------|--|-------------|---|----------------|---------------|
| 1 | TC-1 | 2-(4-chlorodibenzo[b,d]furan-1-yl)-N-(4-fluorobenzyl)-5-methylthiazole 4-carboxamide | 450.91 | C ₂₄ H ₁₆ ClFN ₂ O ₂ S | 78 | 186-188°C |
| 2 | TC-2 | N-(4-chlorobenzyl)-2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methylthiazole 4-carboxamide | 467.36 | C ₂₄ H ₁₆ Cl ₂ N ₂ O ₂ S | 82 | 166-178°C |
| 3 | TC-3 | N-(4-bromobenzyl)-2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methylthiazole 4-carboxamide | 511.82 | C ₂₄ H ₁₆ BrClN ₂ O ₂ S | 76 | 175-178°C |
| 4 | TC-4 | 2-(4-chlorodibenzo[b,d]furan-1-yl)-N-(4-iodobenzyl)-5-methylthiazole-4 carboxamide | 558.82 | C ₂₄ H ₁₆ ClIN ₂ O ₂ S | 75 | 145-147°C |

| | | | | | | |
|----|-------|---|--------|--|----|-----------|
| 5 | TC-5 | 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methyl-N-(4-nitrobenzyl)thiazole-4-carboxamide | 477.92 | C ₂₄ H ₁₆ ClN ₃ O ₄ S | 73 | 152-154°C |
| 6 | TC-6 | 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methyl-N-(4-methylbenzyl)thiazole-4-carboxamide | 446.95 | C ₂₅ H ₁₉ ClN ₂ O ₂ S | 68 | 116-118°C |
| 7 | TC-7 | 2-(4-chlorodibenzo[b,d]furan-1-yl)-N-(4-methoxybenzyl)-5-methylthiazole-4-carboxamide | 462.95 | C ₂₅ H ₁₉ ClN ₂ O ₃ S | 62 | 115-118°C |
| 8 | TC-8 | 2-(4-chlorodibenzo[b,d]furan-1-yl)-N-(4-ethoxybenzyl)-5-methylthiazole-4-carboxamide | 476.98 | C ₂₆ H ₂₁ ClN ₂ O ₃ S | 80 | 162-164°C |
| 9 | TC-9 | 2-(4-chlorodibenzo[b,d]furan-1-yl)-N-(4-ethylbenzyl)-5-methylthiazole-4-carboxamide | 460.98 | C ₂₆ H ₂₁ ClN ₂ O ₂ S | 85 | 158-160°C |
| 10 | TC-10 | 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methyl-N-(4-(trifluoromethyl)benzyl)thiazole-4-carboxamide | 500.92 | C ₂₅ H ₁₆ ClF ₃ N ₂ O ₂ S | 80 | 115-117°C |
| 11 | TC-11 | 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methyl-N-(4-propylbenzyl)thiazole-4-carboxamide | 475.00 | C ₂₇ H ₂₃ ClN ₂ O ₂ S | 75 | 175-177°C |
| 12 | TC-12 | 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methyl-N-(4-propoxybenzyl)thiazole-4-carboxamide | 491.00 | C ₂₇ H ₂₃ ClN ₂ O ₃ S | 78 | 145-147°C |

Characterization of the Synthesized compounds by IR, NMR, MASS and elementary analysis


All substances were analyzed by elemental analysis, mass spectroscopy, infrared spectroscopy, and IR.

IR spectra were recorded on Bruker alpha-II software.

NMR spectra were recorded on C13 Advance Bruker DRX 400 MHz spectrometer.

Mass spectra were recorded on JeolSx 102/DA-6000 mass spectrometer using fast moving bombardment (FAB) technique.

Compound Code: TC-1



IUPAC NAME: 2-(4-chlorodibenzo[b,d]furan-1-yl)-N-(4-fluorobenzyl)-5-methylthiazole-4-carboxamide

Elemental Analysis:

| Elements | C | N | O | S |
|----------|---|---|---|---|
|----------|---|---|---|---|


| | | | | |
|-------------------|-------|------|------|------|
| Calculated | 63.93 | 6.21 | 7.10 | 7.11 |
| Found | 63.92 | 6.20 | 7.09 | 7.12 |

IR (cm⁻¹): 3412(N-H); 3470(C=C-H); 1735 (C=O); 1624–1446 (C=C); 1015(C-N); 792(p-substitution); 1102 (C-F); 855(C-Cl)

¹HNMR (ppm): 4.64 -4.65 (CH₂); 7.05-7.10 (2H, Ar-H); 7.35 (1H, Ar-H); 7.33 – 7.39 (4H, Ar-H); 7.45 (1H, Ar-H); 7.48 -7.50 (1H, Ar-H); 7.62 - 7.63 (1H, Ar-H); 7.90 - 7.92 (1H, Ar-H); 8.38 – 8.40(1H, N-H); 2.90 (3H, CH₃)

FAB Mass (m/z): 450.85

Compound Code: TC-2



IUPACName: N-(4-chlorobenzyl)-2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methylthiazole-4-carboxamide

Elemental Analysis:


| Elements | C | N | O | S |
|-------------------|-------|------|------|------|
| Calculated | 61.68 | 5.99 | 6.85 | 6.86 |
| Found | 61.65 | 5.89 | 6.82 | 6.85 |

IR (cm⁻¹): 3412(N-H); 3470(C=C-H); 1735 (C=O); 1624–1446 (C=C); 1015(C-N); 792 (Parasubstitution); 852 (C-Cl)

¹HNMR (ppm): 2.90 (3H, CH₃); 4.64 -4.65 (2H, CH₂); 7.05-7.10 (2H, Ar-H); 7.35 (1H, Ar-H); 7.33–7.39 (4H, Ar-H); 7.45 (1H, Ar-H); 7.48 - 7.50 (1H, Ar-H); 7.62 - 7.63 (1H, Ar-H); 7.90 - 7.92 (1H, Ar-H); 8.38 – 8.40(1H, N-H).

FAB Mass (m/z): 467.30

Compound Code: TC-3




TC-3**C₂₄H₁₆BrClN₂O₂S****IUPACName:** N-(4-bromobenzyl)-2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methylthiazole-4-carboxamide**Elemental Analysis:**

| Elements | C | N | O | S |
|------------|-------|------|------|------|
| Calculated | 56.32 | 5.47 | 6.25 | 6.26 |
| Found | 56.30 | 5.42 | 6.22 | 6.25 |

IR (cm⁻¹): 3412(N-H);3470 (C=C-H); 1735 (C=O); 1624–1446 (C=C); 1015(C-N); 792 (Para substitution); 850 (C-Cl); 1015(C-Br)

¹HNMR (ppm): 2.90 (3H, CH₃); 4.64 -4.65 (2H, CH₂); 7.05-7.10 (2H, Ar-H); 7.35 (1H, Ar-H); 7.33 – 7.39 (4H, Ar-H); 7.45 (1H, Ar-H); 7.48 - 7.50 (1H, Ar-H); 7.62 - 7.63 (1H, Ar-H); 7.90 - 7.92 (1H, Ar-H); 8.38 – 8.40(1H, N-H).


FAB Mass (m/z): 511.80**Compound Code: TC-4****IUPAC NAME:** 2-(4-chlorodibenzo[b,d]furan-1-yl)-N-(4-iodobenzyl)-5-methylthiazole-4-carboxamide**Elemental Analysis:**

| Elements | C | N | O | S |
|------------|-------|------|------|------|
| Calculated | 51.58 | 5.01 | 5.73 | 5.74 |
| Found | 51.54 | 4.99 | 5.72 | 5.70 |

IR (cm⁻¹): 3412(N-H);3470(C=C-H);1735 (C=O); 1624–1446 (C=C);1015(C-N); 792 (Parasubstitution); 855 (C-Cl)

¹HNMR (ppm): 2.90 (3H, CH₃); 4.56-4.58 (2H, CH₂); 7.05-7.10 (2H, Ar-H); 7.35 (1H, Ar-H); 7.33 – 7.39 (4H, Ar-H); 7.45 (1H, Ar-H); 7.48 - 7.50 (1H, Ar-H); 7.62 - 7.63 (1H, Ar-H); 7.90 - 7.92 (1H, Ar-H); 8.38 – 8.40(1H, N-H).

FAB Mass (m/z):558.80**CompoundCode: TC-5**



IUPACNAME: 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methyl-N-(4-nitrobenzyl)thiazole-4-carboxamide

Elemental Analysis:


| Elements | C | N | O | S |
|------------|-------|------|-------|------|
| Calculated | 60.32 | 8.79 | 13.39 | 6.71 |
| Found | 60.28 | 8.75 | 13.35 | 6.70 |

IR (cm⁻¹): 3412(N-H);3470(C=C-H);1735 (C=O); 1624–1446 (C=C); 1015(C-N); 792 (Parasubstitution);852 (C-Cl); 1356 (N-O); 1558 (N=O)

¹HNMR (ppm): 2.90 (3H, CH₃); 4.64 -4.65 (2H, CH₂); 7.05-7.10 (2H, Ar-H); 7.35 (1H, Ar-H); 7.33 – 7.39 (4H, Ar-H); 7.45 (1H, Ar-H); 7.48 - 7.50 (1H, Ar-H); 7.62 - 7.63 (1H, Ar-H); 7.90 - 7.92 (1H, Ar-H); 8.38 – 8.40(1H, N-H).

FAB Mass (m/z): 477.90

Compound Code: TC-6



IUPAC NAME: 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methyl-N-(methylbenzyl)thiazole-4-carboxamide

Elemental Analysis:


| Elements | C | N | O | S |
|------------|-------|------|------|------|
| Calculated | 67.18 | 6.27 | 7.16 | 7.17 |
| Found | 67.15 | 6.20 | 7.15 | 7.12 |

IR (cm⁻¹): 3412 (N-H);3470(C=C-H);1735 (C=O); 1624–1446 (C=C); 1015(C-N); 792 (Parasubstitution); 850 (C-Cl)

¹HNMR (ppm): 2.90 (3H, CH₃); 4.56-4.58 (2H, CH₂); 7.05-7.10 (2H, Ar-H); 7.35 (1H, Ar-H); 7.33 – 7.39 (4H, Ar-H); 7.45 (1H, Ar-H); 7.48 - 7.50 (1H, Ar-H); 7.62 - 7.63 (1H, Ar-H); 7.90 - 7.92 (1H, Ar-H); 8.38 – 8.40(1H, N-H).

FAB Mass (m/z): 447.10

CompoundCode: TC-7



IUPAC NAME: 2-(4-chlorodibenzo[b,d]furan-1-yl)-N-(4-methoxybenzyl)-5-methylthiazole-4-carboxamide

Elemental Analysis:


| Elements | C | N | O | S |
|------------|-------|------|-------|------|
| Calculated | 64.86 | 6.05 | 10.37 | 6.93 |
| Found | 64.82 | 6.02 | 10.35 | 6.90 |

IR (cm⁻¹): 3412(N-H);3470(C=C-H);1735 (C=O); 1624–1446 (C=C); 1015(C-N); 792 (Parasubstitution); 852 (C-Cl)

¹HNMR (ppm): 2.90 (3H, CH₃); 4.11 (3H, OCH₃); 4.64-4.65 (2H, CH₂); 7.05-7.10 (2H, Ar-H); 7.35 (1H, Ar-H); 7.33 – 7.39 (4H, Ar-H); 7.45 (1H, Ar-H); 7.48 - 7.50 (1H, Ar-H); 7.62 - 7.63 (1H, Ar-H); 7.90 - 7.92 (1H, Ar-H); 8.38 – 8.40(1H, N-H).

FAB Mass (m/z): 462.90

Compound Code: TC-8



IUPAC NAME: 2-(4-chlorodibenzo[b,d]furan-1-yl)-N-(4-ethoxybenzyl)-5-methylthiazole-4-carboxamide

Elemental Analysis:


| Elements | C | N | O | S |
|------------|-------|------|-------|------|
| Calculated | 65.47 | 5.87 | 10.06 | 6.72 |
| Found | 65.45 | 5.82 | 10.02 | 6.70 |

IR (cm⁻¹): 3412(N-H);3470 (C=C-H);1735 (C=O); 1624–1446 (C=C); 1015(C-N);792 (Parasubstitution); 850 (C-Cl)

¹HNMR (ppm): 2.90 (s, 3H, CH₃); 4.64 -4.65 (2H, CH₂); 7.05-7.10 (2H, Ar-H); 7.35 (Ar-H); 7.33 – 7.39 (4H, Ar-H); 7.45 (1H, Ar-H); 7.48 -7.50 (1H, Ar-H); 7.62 - 7.63 (1H, Ar-H); 7.90 - 7.92 (1H, Ar-H); 8.38 – 8.40(1H, N-H).

FAB Mass (m/z): 476.90

Compound Code: TC-9



IUPAC NAME: 2-(4-chlorodibenzo[b,d]furan-1-yl)-N-(4-ethylbenzyl)-5-methylthiazole-4-carboxamide

Elemental Analysis:


| Elements | C | N | O | S |
|------------|-------|------|------|------|
| Calculated | 67.74 | 6.08 | 6.94 | 6.95 |
| Found | 67.72 | 6.05 | 6.90 | 6.92 |

IR (cm⁻¹): 3412(N-H), 3470(C=C-H); 1735 (C=O); 1624–1446 (C=C); 1015(C-N);792 (Parasubstitution); 852 (C-Cl)

¹HNMR (ppm): 2.90 (3H, CH₃); 4.64 -4.65 (2H, CH₂); 7.05-7.10 (2H, Ar-H); 7.35 (1H, Ar-H); 7.33–7.39 (4H, Ar-H); 7.45 (1H, Ar-H); 7.48 - 7.50 (1H, Ar-H); 7.62 - 7.63 (1H, Ar-H); 7.90 - 7.92 (1H, Ar-H); 8.38 – 8.40(1H, N-H).


FAB Mass (m/z): 460.90


Compound code: TC-10



TC-10**C₂₅H₁₆ClF₃N₂O₂S****IUPAC NAME:** 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methyl-N-(4-(trifluoromethyl)benzyl)thiazole-4-carboxamide**Elemental Analysis:**

| Elements | C | N | O | S |
|------------|-------|------|------|------|
| Calculated | 59.94 | 5.59 | 6.39 | 6.40 |
| Found | 59.90 | 5.55 | 6.35 | 6.38 |

IR (cm⁻¹): 3412(N-H); 3470(C=C-H); 1735 (C=O); 1624–1446 (C=C); 1015(C-N); 792 (Para substitution); 1160 (C-F); 850 (C-Cl)**¹HNMR (ppm):** 2.90 (3H, CH₃); 4.56-4.58 (2H, CH₂); 7.05-7.10 (2H, Ar-H); 7.35 (1H, Ar-H); 7.33–7.39 (4H, Ar-H); 7.45 (1H, Ar-H); 7.50-7.52 (1H, Ar-H); 7.62-7.63 (1H, Ar-H); 7.90-7.92 (1H, Ar-H); 8.38 – 8.40(1H, N-H).**FAB Mass (m/z): 500.90****Compound Code: TC-11**



IUPAC NAME: 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methyl-N-(4-propoxybenzyl)thiazole-4-carboxamide

Elemental Analysis:

| Elements | C | N | O | S |
|------------|-------|------|------|------|
| Calculated | 66.05 | 5.71 | 9.78 | 6.53 |
| Found | 66.02 | 5.70 | 9.72 | 6.50 |

IR (cm⁻¹): 3412(N-H);3470(C=C-H);1735(C=O); 1624–1446 (C=C); 1015(C-N);792(Para substitution); 850 (C-Cl)

¹HNMR (ppm): 2.90 (3H, CH₃); 4.64 - 4.65 (2H, CH₂); 7.05-7.10 (2H, Ar-H); 7.35 (1H, Ar-H); 7.33 – 7.39 (4H, Ar-H); 7.45 (1H, Ar-H); 7.50-7.52 (1H, Ar-H); 7.62-7.63 (1H, Ar-H); 7.90 -7.92 (1H, Ar-H); 8.38-8.40(1H, N-H).

FAB Mass (m/z): 491.00

PHARMACOLOGICAL EVALUATION:

Inflammation is the body's response to injury, illness, or damage; symptoms include heat, swelling, redness, discomfort, and changed physiological processes. As a natural defensive reaction to tissue damage brought on by microbial, toxic, or physical stress, inflammation occurs. Chemical mediators released by wounded tissues and migratory cells cause it to occur. The goal of the current investigation was to assess if synthetic drugs may have an anti-inflammatory impact in vitro by preventing protein denaturation.

In vitro anti-inflammatory properties via denaturation of proteins

A solution of 0.2% of bovine serum albumin (BSA) was prepared in tris buffer saline and pH was adjusted to 6.8 using glacial acetic acid. The synthesized compounds (TC-1 to TC 12) of different concentration (25, 50, 100, 200, 300 and 400µg/ml) was prepared using ethanol as solvent. The 50µl of each test drug was transformed to test tubes using micropipette. 5 ml of 0.2% w/v of BSA solution was added to the test tubes. The control consists of 5 ml of 0.2% w/v of BSA solution and 5µl alcohol. The test tubes were heated at 72°C for 5 min and then cooled for 10 min.

The absorbance of these solutions was determined using UV–visible (UV) spectrophotometer at 660 nm. % of Denaturation Inhibition was computed using the control, in which no medication was added. Diclofenac sodium was used as standard and treated similarly for determination of absorbance. The percentage inhibition of protein denaturation was calculated using the following formula.

$$\text{Percentage inhibition of protein denaturation} = \frac{AC-AE}{AC} \times 100$$

RESULT AND DISCUSSION

Chemistry

The target structures of the synthesized compounds were characterized by elemental, mass spectral, IR, and NMR examinations. Compound 2 was produced via the 4-chlorodibenzo[b,d]furan (0.02M) reaction. Compound 1 has a solid pale brown color, a yield of 82%, and a mass (m/z) of 263.74 with methane sulfonic acid.S-((4-chlorodibenzo[b,d]furan-1 yl)methyl) thiohydroxylamine (0.02M) was used to create compound 3.To get a peach-

colored solid (Compound 3), combine Compound 2 with potassium carbonate and ethyl 3-bromo-2-oxobutanoate (0.02M); yield: 72.50%; mass (m/z): 371.84. Ethyl 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methylthiazole-4-carboxylate (0.01M), (Compound 3) and aqueous potassium hydroxide solution were reacted to create Compound 4, an off-white solid with a yield of 72% and a mass (m/z) of 343.78%. 2-(4-chlorodibenzo[b,d]furan-1-yl)-5-methylthiazole-4-carboxylic acid (0.02M), compound 4, and substituted benzyl amine reacted to create the final chemical (Compound 5).

The compound TC-1 to TC-12 has characterized by the IR, ¹HNMR, elemental and Mass spectral analysis. The IR spectrum of the compounds has shown the characteristics peak (cm⁻¹) of N-H at 3412; C=C-H at 3470; C=O at 1735; C=C at 1624–1446; C-N at 1015; p-substitution at 792; C-F at 1102; C-Cl at 855; C-Br at 1015; N-O at 1356; N=O at 1558. The ¹HNMR spectra of Final compounds (TC-1 to TC-12) depicted the peak at 2.90 (3H, CH₃); 4.64 - 4.65 (2H, CH₂); 7.05-7.10 (2H, Ar-H); 7.35 (1H, Ar-H); 7.33 – 7.39 (4H, Ar-H); 7.45 (1H, Ar-H); 7.48 - 7.50 (1H, Ar-H); 7.62 - 7.63 (1H, Ar-H); 7.90 - 7.92 (1H, Ar-H); 8.38 – 8.40 (1H, N-H).

Compound TC-1, mass spectrum have shown peak at m/z = 450.85, which matches the chemical formula C₂₄H₁₆ClF₂N₂O₂S. All the other synthesized compound has also shown the molecular ion peak similar to their molecular formula and weight.

In-vitro anti-inflammatory activity

Protein denaturation

An examination of the synthetic compounds' capacity to denaturize proteins was conducted in order to assess their anti-inflammatory properties. It proved successful in preventing the denaturation of proteins caused by heat. A common anti-inflammatory drug with greatest percentage inhibition is diclofenac sodium. Table No. 3 showed how the synthetic chemicals (TC-1 to TC-12) affected protein denaturation.


Table 3: The percentage inhibition as protein denaturation of synthesized compounds (TC-1 to 12)

| S. No. | Compounds | 25 | 50 | 100 | 200 | 300 | 400 |
|--------|-------------------|-------|-------|-------|-------|-------|-------|
| 1 | TC-1 | 21.47 | 30.77 | 41.03 | 53.00 | 57.58 | 82.38 |
| 2 | TC-2 | 27.44 | 33.50 | 51.30 | 54.98 | 56.85 | 88.96 |
| 3 | TC-3 | 16.06 | 21.89 | 36.08 | 41.83 | 42.61 | 77.03 |
| 4 | TC-4 | 15.60 | 33.50 | 50.68 | 56.85 | 62.99 | 84.36 |
| 5 | TC-5 | 24.76 | 43.86 | 57.71 | 66.30 | 69.37 | 89.06 |
| 6 | TC-6 | 16.50 | 17.81 | 35.11 | 37.08 | 38.91 | 55.49 |
| 7 | TC-7 | 3.02 | 10.75 | 32.26 | 39.57 | 53.91 | 65.30 |
| 8 | TC-8 | 6.04 | 7.42 | 15.70 | 19.76 | 25.16 | 48.63 |
| 9 | TC-9 | 8.72 | 18.24 | 32.07 | 36.11 | 48.59 | 65.77 |
| 10 | TC-10 | 4.40 | 05.46 | 21.23 | 32.32 | 38.99 | 62.03 |
| 11 | TC-11 | 2.40 | 04.02 | 11.50 | 28.54 | 32.35 | 58.30 |
| 12 | TC-12 | 1.15 | 08.02 | 21.05 | 15.36 | 35.23 | 60.20 |
| 13 | Diclofenac Sodium | 14.20 | 40.32 | 53.77 | 62.49 | 67.22 | 84.94 |

(Values are Mean±S.E.M., where n=6) in each group, P< 0.05 *, P< 0.01** (significant) compared with control.

Statistical analysis was done by one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison test.

The result data of protein denaturation assay denotes that compound TC-1 has shown the 82.38% of inhibition, compound TC-2 has shown the 88.96% inhibition, compound TC-3 has shown the 77.03% inhibition compound TC-4 has shown the 84.36% of inhibition, TC 5 has shown 89.06% of inhibition. The compound TC-1, TC-2, TC-3, TC-4, and TC-5 has shown the better activity as percentage of inhibition compare to diclofenac sodium (84.94%).



Graph 1:- Percentage of inhibition of synthesized compound (TC-1 to TC-12) as compared to diclofenac sodium

The data of protein denaturation assay result stated that compound TC-6, TC-7, TC-8, TC-9, TC-10, TC-11 and TC-12 has shown the mild activity as compared to the standard drug. The compound TC-6 has shown the 55.49% inhibition, compound TC-7 has shown the 65.30% inhibition, compound TC-8 has shown the 48.63% inhibition, compound TC-9 has shown the 65.77% inhibition, compound TC-10 has shown the 62.03% inhibition, compound TC-11 has shown the 58.30% inhibition and compound TC-12 has shown the 60.20% inhibition. The most active compound TC-1, TC-2, TC-3, TC-4 and TC-5, the compounds TC-7 & TC-9 has shown the mild activity and compound TC-6, TC-8, TC-10, TC-11 and TC-12 has shown modest activity.

CONCLUSION:

The synthesis of twelve substances is reported in the current article, "Synthesis of dibenzofuran-1,3-thiazole carboxamide derivatives and screened for anti-inflammatory potential." It is commonly known that the existence of compounds derived from dibenzofuran-1,3-thiazole carboxamide has produced pharmacologically and physiologically active drugs with a variety of heterocyclic structural types.

The compounds' structures were verified by the use of mass spectroscopy, FTIR, ¹HNMR, and melting point measurements. TC-1, TC-2, TC-3, TC-4, and TC-5 in particular shown promising activity when compared to the reference medication diclofenac sodium. This investigation revealed that the halogenic derivative with para substitution is primarily responsible for the dibenzofuranthiazole carboxamide derivatives' anti-inflammatory effect. One of the main groups that significantly improved the activity with the para substituent was the fluoro, chloro, bromo, iodo, and nitro substitution.

REFERENCES:

1. Eleftheriou P, Geronikaki A, Hadjipavlou-Litina D, Vicini P, Filz O, Filimonov D, Poroikov V, Chaudhaery SS, Roy KK, Saxena AK. Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzisothiazolimino-5-arylidene-4-thiazolidinones as cyclooxygenase lipooxygenase inhibitors. *Eur J Med Chem.* 2012;47: 111–124.
2. Mylari BL, Larson ER, Beyer TA. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid and congeners, *J Med Chem* 1991; 34(1): 108–122.
3. Van Zandt MC, Jones ML, Gunn DE. Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-*N*-acetic acid and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications. *J Med Chem* 2005; 48(9): 3141–3152
4. Sherif SM, Mohareb RM, Shams HZ, Gaber HM. A convenient synthesis of polyfunctionally substituted benzo [*b*]thiophen-2-yl-pyrimidine, -pyrazole, -isoxazole and pyridazine derivatives. *J Chem Res* 1995; 11: 434–435.
5. Bansal S, Bala M, Suthar SK, Choudhary S, Bhattacharya S, Bhardwaj V, Singla S, Joseph A. Design and synthesis of novel 2-phenyl-5-(1,3-diphenyl-1H-pyrazol-4-yl)-1,3,4-oxadiazoles as selective COX-2 inhibitors with potent anti-inflammatory activity. *Eur J Med Chem* 2014; 80: 167–174.

6. Penrose JF, Austen KF, Lam BK. Leukotrienes: Biosynthetic Pathways, Release and Receptor-Mediated Actions with Relevance to Disease States. In *Inflammation: Basic Principles and Clinical Correlates*; Gallin JL, Snyderman R, Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 1999; pp. 361–372
7. Bondock S, Fouda AM. Synthesis and evaluation of some new 5-arylthiazoles as potential antimicrobial agents. *Synth Commun* 2018;48: 561–573.
8. Ashok D, SreeKanth S, Sarasija M, Vijiulatha M. Synthesis biological evaluation and molecular docking of spirofurochromanone derivative as anti-inflammatory and anti-oxidant agents. *Royal Society Chem* 2017; 7: 5710-25724
9. Gopal B, Sukunath N, Lavanya A, Thirunavukarasu S. In-vivo effective dibenzo(b,d)furan-1-yl-thiazoles as novel PDE-4 inhibitors. *Bioorg Med Chem* 2016; 24: 5702-5716.
10. Mohareb RM, Zaki MY, Abbas NS. Synthesis, anti-inflammatory and anti-ulcer evaluations of thiazole, thiophene, pyridine and pyran derivatives derived from androstenedione. *Steroids* 2015;98: 80–91.
11. Srinivas K, Thirumal Y, Govardhan S, Balasubramanian A. Synthesis of antitubercular evaluation of novel dibenzo(b,d)furan and 9-methyl-9H-Carbazole derived hexahydro-2H-Pyrano(3,2-c)quinolones via Povarov reaction. *Eur J Med Chem* 2016;46: 4827-4833.
12. Sangita C, Priyanka C, Protapaditya D, Sanjib B. Evaluation of in vitro anti-inflammatory activity of coffee against the denaturation of protein. *Asian Pacific J Trop Biomed* 2012; 3(2):178-180.